Of course, near-complete inhibition of p53 during embryogenesis is unlikely to be a clinically viable approach for preventing CHARGE syndrome phenotypes, given the strong association between p53 loss and tumorigenesis. This evidence concerns the gene TP53 and CHARGE syndrome.